Monthly research recap
Depression research: March 2026
What March 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
In March 2026, depression research focused heavily on treatment-resistant depression (TRD), with ketamine/esketamine and psychedelics (psilocybin, 5-MeO-DMT) showing rapid antidepressant effects, though a meta-analysis found psychedelic therapy no more effective than open-label antidepressants. Real-world and trial data consistently support esketamine's efficacy and cognitive safety, but durability and long-term safety remain key caveats.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Therapist Manual for Psilocybin-Assisted Therapy of Treatment-Resistant Major Depression 2026 | phase IIb randomized clinical trial | Supports | Provides a standardized therapeutic framework for psilocybin-assisted therapy in TRD, including structured music use and safety monitoring. | |
| Ketamine as a Rapid-Acting Antidepressant: A Scoping Review of Mechanisms and Efficacy in Treatment-Resistant Depression. 2026 | scoping review | Supports | Ketamine provides rapid antidepressant effects in TRD through glutamatergic modulation, but long-term safety and dependence risk require monitoring. | |
| Neuroimaging insights from Wistar-Kyoto rats under chronic mild stress: morphological and metabolic brain correlates of treatment-resistant depression. 2026 | preclinical animal study | Supports | The WKY/CMS rat model shows reduced glutamate, glutamine, and taurine in the prefrontal cortex and decreased glutamine and choline compounds in the hippocampus, with increased mean diffusivity and reduced fractional anisotropy, consistent with depression-related changes. | |
| Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review 2026 | review | Supports | The therapeutic effects of (R,S)-ketamine involve specific brain circuits and BDNF-TrkB signaling, while NMDA receptor antagonism may be unrelated to efficacy. | |
| Preventing Depression through Selflessness: Effects and Mechanisms of Attentional vs. Deconstructive Meditation in a Three–Arm Randomized Controlled Trial 2026 | randomized controlled trial | 147 | Supports | Both focused-attention and self-inquiry meditation reduced depressive symptoms and identity threat compared to wait-list control, with focused-attention also reducing dysfunctional attitudes more than self-inquiry. |
| Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies 2026 | review | Supports | Recent discoveries of rapid-acting antidepressant effects of ketamine and psychedelic compounds have challenged traditional monoaminergic models and highlighted alternative mechanisms involving glutamatergic signaling, synaptic plasticity, and immune-brain interactions. | |
| GH001 vs Placebo in Patients With Treatment-Resistant Depression 2026 | randomized controlled trial | 81 | Supports | Inhaled GH001 produced significantly greater reduction in depression severity than placebo by day 8, with a 57.5% remission rate versus 0% in the placebo group. |
| The Feasibility and Acceptability of Personalised Smart-Messaging To Enhance Remote Mindfulness-Based Cognitive Therapy for Recurrent Depression 2026 | feasibility study | Supports | Personalized smart-messaging is feasible and acceptable as an enhancement to remote mindfulness-based cognitive therapy for recurrent depression. | |
| Cognitive Effects of Esketamine in Treatment-Resistant Depression: A Systematic Review. 2026 | systematic review | Supports | Esketamine appears cognitively safe in adults with TRD and may improve attention and processing speed, with more variable benefits in memory and executive functioning over sustained treatment. | |
| Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial. 2026 | proof-of-concept trial | Supports | Intranasal 5-MeO-DMT combined with an SSRI was well tolerated and showed preliminary antidepressant effects in TRD. | |
| Psilocybin: Chemical Foundations and Emerging Therapeutic Potential. 2026 | review | Supports | Psilocybin shows therapeutic potential for depression and other conditions, but large-scale synthesis remains challenging due to complex chemical processes. | |
| Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes. 2026 | retrospective longitudinal cohort study | 50 | Supports | Esketamine nasal spray produced progressive improvements in depressive symptoms and functioning, with higher baseline treatment refractoriness predicting lower odds of response and remission. |
| [Esketamine alleviates depression-like behaviors in mice with chronic restraint stress by activating glutamatergic neurons in the medial prefrontal cortex]. 2026 | randomized controlled trial | 150 | Supports | Esketamine's antidepressant effects in chronically stressed mice depend on activating glutamatergic neurons in the medial prefrontal cortex. |
| Role of Anesthesia in ECT for Major Depressive Disorder. 2026 | systematic review | Mixed | Ketamine and etomidate are associated with longer seizures than other anesthetics, and lower doses or longer intervals between anesthesia and ECT may improve seizure duration and response, though clinical outcomes are generally similar across agents. | |
| Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions 2026 | systematic review and meta-analysis | 24 | No effect | Psychedelic-assisted therapy was no more effective than open-label traditional antidepressants for treating major depression. |
| Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression 2026 | randomized clinical trial | 144 | No effect | Psilocybin 25 mg with psychotherapy did not produce a statistically significant difference in treatment response compared to placebo at six weeks, though exploratory analyses indicated a clinically meaningful reduction in depressive symptoms. |
| Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response. 2026 | observational cohort | Supports | Intranasal esketamine is effective in real-world treatment of TRD, with response influenced by patient-specific factors. | |
| Explainable AI framework for psilocybin depression treatment optimization 2026 | computational modeling study | 60 | Supports | The computational framework achieved 94.7% prediction accuracy and 89.3% explainability scores in simulated environments for optimizing psilocybin treatment protocols. |
| Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein. 2026 | secondary analysis of an open-label trial | 22 | Mixed | Patients with elevated baseline CRP showed significant within-group reductions in CRP over time, but these changes did not correlate with depressive symptom improvement. |
| Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review 2026 | narrative review | Supports | Esketamine may reduce drug-seeking behavior and cravings in patients with TRD and comorbid substance use disorders, especially when combined with behavioral interventions. | |
| Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports. 2026 | case series | 3 | Supports | Intranasal esketamine as add-on therapy reduced depressive symptoms and suicidal ideation in three patients with autism and TRD, with two achieving remission at six months. |
| LLM-Augmented Therapy Normalization and Aspect-Based Sentiment Analysis for Treatment-Resistant Depression on Reddit 2026 | observational study | 3480 | Mixed | Conventional antidepressants show consistently higher negative than positive sentiment proportions, while ketamine and esketamine show comparatively more favorable sentiment profiles in Reddit discourse. |
| Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS. 2026 | observational cohort | Supports | Intranasal esketamine and accelerated rTMS showed comparable real-world effectiveness for TRD. | |
| Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities 2026 | review | Supports | Individuals with comorbid Substance Use Disorders are overrepresented among responders to ketamine for TRD, and the authors urge careful consideration of risks and benefits. | |
| Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response 2026 | preclinical study | Supports | Coadministration of PDE9i with psilocybin reduces psychedelic-like behavior while maintaining antidepressant effects in a mouse model of chronic stress. |
Points of agreement
- Ketamine and esketamine are consistently reported as effective rapid-acting antidepressants for treatment-resistant depression across multiple study types.
- Psychedelic-assisted therapies (psilocybin, 5-MeO-DMT) show promise in reducing depressive symptoms, though some trials fail to show superiority over placebo or open-label antidepressants.
- Real-world studies support the effectiveness of esketamine nasal spray in clinical practice, with improvements in depressive symptoms and functioning.
- Cognitive safety of esketamine is supported, with potential improvements in attention and processing speed.
- Mechanistic studies highlight glutamatergic signaling and synaptic plasticity as key pathways for rapid-acting antidepressants.
Conflicts
- A meta-analysis found psychedelic therapy no more effective than open-label antidepressants, while individual trials (e.g., GH001) show significant superiority over placebo.
- A phase 2b trial of psilocybin for TRD did not find a statistically significant difference from placebo at six weeks, conflicting with other positive psilocybin findings.
- The role of NMDA receptor antagonism in ketamine's efficacy is debated, with some reviews suggesting it may be unrelated to therapeutic effects.
Gaps
- Long-term durability of antidepressant effects for ketamine, esketamine, and psychedelics remains understudied.
- Most psychedelic trials have high functional unblinding, limiting interpretation of efficacy compared to standard antidepressants.
- Real-world studies often lack control groups and rely on retrospective data, limiting causal inference.
- Specific populations (e.g., comorbid autism, substance use disorders) are underrepresented in larger trials.
- Dose optimization and personalized treatment protocols for psychedelics are still in early stages, with limited clinical validation.